# name
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

# metadata.dc.description.abstract[].value
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first-line chemo immunotherapy. In recent years, there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL. These agents include anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) and monoclonal antibody therapies such as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are in clinical development to treat R/R DLBCL.

# metadata.dc.relation.ispartof[].value
Journal of Clinical Medicine, 2023, vol. 12, num. 23, p. 7376

# metadata.dc.rights[].value
cc by (c) Gonzalez Barca, Eva et al., 2023

# metadata.dc.source[].value
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma